DDInter1665 DDInter899
Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Sibutramine {u} (Compound) treats {v} (Disease) obesity
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
Sibutramine {u} (Compound) upregulates {v} (Gene) CDK6
Sibutramine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Sibutramine {u} (Compound) downregulates {v} (Gene) MRPL19
Sibutramine {u} (Compound) causes {v} (Side Effect) Bursitis
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Grepafloxacin
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tinzaparin
Sibutramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Halazepam
Sibutramine (Compound) treats obesity (Disease)
Sibutramine (Compound) binds CYP3A4 (Gene)
Sibutramine (Compound) upregulates CDK6 (Gene)
Sibutramine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Sibutramine (Compound) downregulates MRPL19 (Gene)
Sibutramine (Compound) causes Bursitis (Side Effect)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam